Get notified when TRAW files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company and its auditor have expressed substantial doubt about its ability to continue as a going concern, with cash only sufficient into Q1 2027.
- Material Weakness (new) — The company has in the past identified, and in the future may identify, material weaknesses in its internal control over financial reporting.
- Clinical Hold (new) — The FDA placed the US IND for lead program tivoxavir marboxil on clinical hold due to toxicology data concerns.
Traws Pharma launches at-the-market offering to sell up to $5.6M of common stock at $0.70/share
Filed July 10, 2026 · ~2 min read
Key Changes
-
high
Traws Pharma may sell up to $5,575,709 of common stock in an at-the-market offering through Citizens JMP Securities, with a 3.0% commission on gross proceeds.
The Offering verify on EDGAR → -
high
New investors pay $0.70 per share and face immediate dilution of $0.45 per share, as pro forma as adjusted net tangible book value is only $0.25 per share.
Dilution verify on EDGAR → -
high
The company has expressed substantial doubt about its ability to continue as a going concern, with cash only sufficient to fund operations into Q1 2027.
Risk Factors verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade TRAW commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify